Belite Bio will present data on Tinlarebant for Stargardt disease at upcoming ophthalmology congresses in Switzerland and Australia.
Quiver AI Summary
Belite Bio, Inc. has announced that it will present data on its lead therapy, tinlarebant, at two upcoming ophthalmology congresses: the Schweizerische Ophthalmologische Gesellschaft Annual Congress in Lausanne, Switzerland, and the Asia-Pacific Vitreo-retina Society Congress in Gold Coast, Australia. The presentations will focus on results from the Phase 3 Dragon Study, which evaluated tinlarebant for treating Stargardt disease, a common inherited macular dystrophy that currently has no approved treatments. Tinlarebant works by reducing toxic bisretinoid accumulation in the retina. The drug has received several designations to expedite its development due to its potential in addressing significant unmet needs in retinal diseases.
Potential Positives
- Belite Bio's data presentation at two significant ophthalmology congresses highlights the company's commitment to advancing its research and development efforts for novel therapies targeting degenerative retinal diseases.
- The Phase 3 Dragon Study results for tinlarebant, presented by notable physicians, may enhance the credibility and visibility of Belite Bio within the medical community, potentially attracting further interest from investors and collaborators.
- Tinlarebant's multiple designations, including Breakthrough Therapy and Fast Track, underscore its potential impact and significance, particularly given the lack of approved treatments for Stargardt disease.
- Belite Bio's focus on unmet medical needs in degenerative retinal diseases positions the company strategically in a niche market, which may lead to future growth and opportunities for the company's therapeutic pipeline.
Potential Negatives
- Presentation of the data at upcoming congresses may indicate that the company is still in the trial phase and has not yet reached commercialization, reflecting potential delays in bringing their therapy to market.
- The mention of multiple presentations suggests that results might be mixed or unclear, which could impact investor confidence if outcomes are not positively received.
- Despite having received several designations from regulatory bodies, the absence of approved treatments highlights the competitive and uncertain nature of this therapeutic area, which could affect future funding and support.
FAQ
What are the upcoming conferences where Belite Bio will present data?
Belite Bio will present at the SOG Annual Congress and APVRS Congress in August 2026.
Who is presenting the Dragon Study results at SOG?
Dr. Hoai Viet Tran will present the Phase 3 Dragon Study results for Stargardt Disease at SOG.
What is Tinlarebant and its purpose?
Tinlarebant is an oral therapy aimed at reducing vitamin A-based toxins in Stargardt Disease and advanced dry AMD.
What designations has Tinlarebant received?
Tinlarebant has received Breakthrough Therapy, Fast Track, and Orphan Drug Designation in the U.S., and designations in Europe and Japan.
What is Stargardt Disease?
Stargardt Disease is the most common inherited macular dystrophy, causing progressive vision loss due to bisretinoid accumulation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BLTE Insider Trading Activity
$BLTE insiders have traded $BLTE stock on the open market 119 times in the past 6 months. Of those trades, 0 have been purchases and 119 have been sales.
Here’s a breakdown of recent trading of $BLTE stock by insiders over the last 6 months:
- HENDRIK PETER SCHOLL (Chief Medical Officer) has made 0 purchases and 13 sales selling 20,000 shares for an estimated $2,858,164.
- NATHAN L. MATA (Chief Scientific Officer) has made 0 purchases and 93 sales selling 15,000 shares for an estimated $2,411,919.
- YU-HSIN LIN (Chief Executive Officer) has made 0 purchases and 6 sales selling 9,565 shares for an estimated $1,735,166.
- HAO-YUAN CHUANG (Chief Financial Officer) has made 0 purchases and 6 sales selling 6,567 shares for an estimated $1,191,490.
- WAN-SHAN CHEN sold 1,100 shares for an estimated $198,473
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BLTE Hedge Fund Activity
We have seen 51 institutional investors add shares of $BLTE stock to their portfolio, and 52 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 543,370 shares (-70.7%) from their portfolio in Q2 2026, for an estimated $83,670,829
- RA CAPITAL MANAGEMENT, L.P. removed 432,484 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $68,955,248
- MAVERICK CAPITAL LTD added 396,311 shares (+inf%) to their portfolio in Q2 2026, for an estimated $61,025,949
- LOGOS GLOBAL MANAGEMENT LP added 250,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $38,496,250
- HOLOCENE ADVISORS, LP removed 243,460 shares (-49.2%) from their portfolio in Q2 2026, for an estimated $37,489,188
- MARSHALL WACE, LLP removed 192,700 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $30,724,088
- CITADEL ADVISORS LLC added 184,160 shares (+9171.3%) to their portfolio in Q2 2026, for an estimated $28,357,877
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BLTE Price Targets
Multiple analysts have issued price targets for $BLTE recently. We have seen 4 analysts offer price targets for $BLTE in the last 6 months, with a median target of $208.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $200.0 on 06/15/2026
- Graig Suvannavejh from Mizuho set a target price of $215.0 on 05/26/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $266.0 on 03/03/2026
- Judah Frommer from Morgan Stanley set a target price of $201.0 on 03/03/2026
Full Release
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia.
SOG Presentation Details
Session:
Free Communications I – Retina Vitreous
Title:
Results from the Phase 3 Dragon Study of Tinlarebant for Adolescent and Adult Stargardt Disease
Presenter:
Dr.med. Hoai Viet Tran, FMH, FEBO, Consultant Physician, Head of the Ocular Genetics & Gene Therapy Unit, Department of Ophthalmology, University of Lausanne, Hôpital ophtalmique Jules-Gonin, Fondation Asile des aveugles
Date and Time:
August 27, 2026, 8:30 – 8:40 p.m. CEST
Location:
SwissTech Convention Center, EPFL Campus, Lausanne, Switzerland
APVRS Presentation Details
Session:
Late Breaking Symposium
Title:
New Insights from the DRAGON Study of Tinlarebant for Stargardt’s Disease
Presenter:
Quan Dong Nguyen, M.D., Professor of Ophthalmology at the Byers Eye Institute and Professor of Pediatrics and Professor of Medicine (Immunology and Rheumatology), Stanford University School of Medicine
Date and Time:
August 30, 2026, 8:00 – 8:08 a.m. AEST
Location:
Gold Coast Convention & Exhibition Centre
Session:
Rapid Fire 6 - Myopia (1), Retina (Surgical) (1) and Retina (Medical) (6)
Title:
Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt’s Disease
Presenter:
John Grigg, M.D., Professor of Clinical and Experimental Ophthalmology and Head of the Discipline of Ophthalmology at The University of Sydney's Save Sight Institute, Consultant, Sydney Eye Hospital and The Children's Hospital Westmead
Date and Time:
August 30, 2026, 12:10-12:15 p.m. AEST
Location:
Gold Coast Convention & Exhibition Centre
Session:
Inherited Retinal Diseases and Electrophysiology
Title:
Update on ABCA4-Retinopathy Therapy: Therapeutic Trials in Japan
Presenter:
Kaoru Fujinami, M.D., Ph.D., Professor of the National Institute of Sensory Organs at National Hospital Organization Tokyo Medical Center, and Honorary Professor of the University College London Institute of Ophthalmology.
Date and Time:
August 29, 2026, 11:36-11:48 a.m. AEST
Location:
Gold Coast Convention & Exhibition Centre
About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.
About Stargardt Disease
STGD1 is the most common inherited macular dystrophy in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of high-resolution retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no approved treatments for STGD1.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com .
Media and Investor Relations Contact:
[email protected]
